<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Liver transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection of the liver allograft</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Liver transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection of the liver allograft</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Liver transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection of the liver allograft</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott J Cotler, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Brown, Jr, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The use of potent immunosuppressive agents for induction and maintenance therapy for liver transplantation has reduced the incidence of acute rejection, which is defined as liver allograft dysfunction associated with specific pathologic changes in the graft. With use of immunosuppression protocols, acute T cell-mediated (cellular) rejection (TCMR) occurs in approximately 10 to 30 percent of liver transplantation recipients [<a href="#rid1">1-4</a>].</p><p>Acute rejection can be broadly categorized into TCMR and antibody-mediated (previously known as humoral) rejection (AMR). A liver allograft biopsy is required to establish the diagnosis and determine the severity of rejection in order to guide treatment. </p><p>The focus of this topic is treatment of acute TCMR of the liver allograft. The clinical features and diagnostic evaluation of patients with suspected acute TCMR are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4587.html" rel="external">"Liver transplantation in adults: Clinical manifestations and diagnosis of acute T-cell mediated (cellular) rejection of the liver allograft"</a>.)</p><p>The approach to immunosuppression following liver transplantation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4586.html" rel="external">"Liver transplantation in adults: Initial and maintenance immunosuppression"</a>.)</p><p>Infectious complications in liver transplant recipients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">"Infectious complications in liver transplantation"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>Therapy for patients with acute TCMR of the liver allograft is guided by pretreatment evaluation, which excludes other causes of graft dysfunction and determines the severity of rejection. The diagnostic evaluation typically includes the following tests (see  <a class="medical medical_review" href="/z/d/html/4587.html" rel="external">"Liver transplantation in adults: Clinical manifestations and diagnosis of acute T-cell mediated (cellular) rejection of the liver allograft", section on 'Diagnostic evaluation'</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Liver biochemical tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, and total bilirubin).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug concentration levels for patients on <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory tests to exclude infection for patients with suspected infection (eg, cytomegalovirus [CMV] antigen). (See  <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">"Infectious complications in liver transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver ultrasound with Doppler study to exclude hepatic artery or portal vein thrombosis or signs of biliary obstruction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biopsy of liver allograft to determine rejection severity and to assess for other conditions (eg, ischemic injury, biliary abnormality, drug-induced liver injury, viral infection such as CMV, recurrence of primary liver disease, antibody-mediated rejection [AMR]). (See <a class="local">'Defining severity of rejection'</a> below.)</p><p></p><p>AMR is a less common cause of allograft injury and loss after ABO-compatible liver transplantation that can mimic or overlap with acute TCMR. The differential diagnosis of acute TCMR of the liver allograft is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4587.html" rel="external">"Liver transplantation in adults: Clinical manifestations and diagnosis of acute T-cell mediated (cellular) rejection of the liver allograft", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H3913098154"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H587665604"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>Treatment goals for patients with acute TCMR include:</p><p class="bulletIndent1"><span class="glyph">●</span>Improving liver biochemical tests and liver histology</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preventing chronic rejection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding adverse impact on long-term graft survival [<a href="#rid5">5</a>]</p><p></p><p class="headingAnchor" id="H2392686491"><span class="h2">Measures for all patients</span></p><p class="headingAnchor" id="H4130419559"><span class="h3">Optimizing baseline immunosuppression</span><span class="headingEndMark"> — </span>For all patients with histologic evidence of acute TCMR of the liver allograft, the baseline maintenance immunosuppressive regimen is assessed and optimized, while the specific approach depends on the patient's drug regimen and baseline kidney function. (See <a class="local">'Defining severity of rejection'</a> below.)</p><p>Options for optimizing immunosuppression are the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> – For patients on tacrolimus as part of their baseline regimen, the dose is often adjusted to target a higher drug level. For example, for patients with a tacrolimus level in the 3 to 5 ng/ml range, the dose might be increased to achieve tacrolimus levels in the 5 to 7 ng/mL range provided that the patient has no or only mild chronic kidney disease at baseline (estimated glomerular filtration rate [eGFR] &gt;60 mL/min/1.73 m<sup>2</sup>) and does not develop calcineurin-related nephrotoxicity. Acute and chronic nephrotoxicity related to tacrolimus are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> is used for primary immunosuppression at most liver transplantation centers; however, patients with acute TCMR who are being treated with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> may be switched to tacrolimus [<a href="#rid6">6,7</a>]. Indirect evidence has suggested that switching from cyclosporine to tacrolimus may provide benefit for some patients with acute rejection [<a href="#rid8">8,9</a>]. In a series of 18 patients with acute TCMR refractory to initial therapy with either glucocorticoids or muromonab-CD3 (OKT3, no longer available), conversion to tacrolimus was associated with liver biochemical and histologic improvement in 10 patients (56 percent) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> dosing, adverse effects, and efficacy as primary immunosuppression are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4586.html" rel="external">"Liver transplantation in adults: Initial and maintenance immunosuppression", section on 'Calcineurin inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> – For patients on mycophenolate, the dose may be increased.</p><p></p><p class="bulletIndent1">For patients who are not receiving an antimetabolite agent as part of the baseline immunosuppressive regimen, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> may be added. Antimetabolite agents interfere with the synthesis of nucleic acids and inhibit the proliferation of both T and B lymphocytes. Mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS) is the antimetabolic agent used for most liver and kidney transplant recipients in the United States; <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> is occasionally used. (See  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1">The recommended dose of MMF is 2 g daily by mouth in two divided doses. Adverse effects of <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> include gastrointestinal symptoms (ie, diarrhea, nausea, anorexia) and dose-related bone marrow suppression. Initiating MMF at a reduced dose (ie, 500 mg twice daily) and then titrating the dose upward may improve tolerability. </p><p></p><p class="bulletIndent1">EC-MPS, an enteric-coated formulation of <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>, was developed to try to improve the upper gastrointestinal tolerability of mycophenolate. However, EC-MPS and MMF doses are not equivalent. The dosing range for mycophenolate sodium is 360 to 720 mg orally twice daily. For specific dosing information, refer to the Lexicomp drug database and the drug label, while dosing conversion is also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1">The use of MMF has been associated with improvement in liver biochemical tests and histology for liver transplantation recipients with acute rejection [<a href="#rid10">10-13</a>]. In an observational study of 47 patients with acute rejection refractory to glucocorticoids, adding MMF to the existing drug regimen (ie, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>) was associated with normalization of liver biochemical tests in 38 patients (81 percent) [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H496855204"><span class="h2">Defining severity of rejection</span><span class="headingEndMark"> — </span>A classification system for acute TCMR was developed by a panel of experts who agreed on a nomenclature and histopathologic criteria for grading acute rejection (ie, Banff classification) [<a href="#rid14">14</a>].The management of patients with histologic evidence of acute TCMR is guided by histopathologic severity of rejection. (See <a class="local">'Pretreatment evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/4587.html" rel="external">"Liver transplantation in adults: Clinical manifestations and diagnosis of acute T-cell mediated (cellular) rejection of the liver allograft", section on 'Establishing the diagnosis'</a>.)</p><p>Three specific histologic features associated with acute TCMR are (<a class="graphic graphic_table graphicRef74243" href="/z/d/graphic/74243.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Mixed portal inflammatory infiltrate</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bile duct epithelial inflammation and damage</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Venous endothelial inflammation</p><p></p><p>Each of these parameters is given a score, and the sum of the scores is called the rejection activity index (RAI) [<a href="#rid14">14,15</a>]. Rejection severity is determined by RAI values. Mild rejection has been regarded as RAI ≤4, while classification of RAI values has varied among studies [<a href="#rid14">14-21</a>]. (See <a class="local">'Patients with RAI ≤4'</a> below and <a class="local">'Patients with RAI ≥5'</a> below.)</p><p class="headingAnchor" id="H3582625593"><span class="h3">Patients with RAI ≤4</span><span class="headingEndMark"> — </span>Initial treatment for patients with mild acute TCMR based on histologic evidence (ie, rejection activity index [RAI] ≤4) typically includes optimizing the baseline immunosuppressive regimen (<a class="graphic graphic_algorithm graphicRef129097" href="/z/d/graphic/129097.html" rel="external">algorithm 1</a>). However, the specific approach depends on the patient's existing immunosuppressive medications. (See <a class="local">'Measures for all patients'</a> above.) </p><p>Monitoring laboratory testing is required after augmenting the baseline immunosuppressive regimen. We obtain liver biochemical tests (ie, alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, and total bilirubin) weekly after adjusting immunosuppressive medications. For patients who do not have improvement in liver biochemical tests within four weeks or who have increasing elevations in liver tests, we generally repeat the biopsy of the liver allograft to reassess rejection severity. Patients without histologic improvement or with histologic progression after optimizing immunosuppression are regarded as having moderate to severe rejection and are typically treated with glucocorticoids. (See <a class="local">'Patients with RAI ≥5'</a> below.)</p><p>Patients with histologic improvement or resolution are continued on maintenance immunosuppression. (See  <a class="medical medical_review" href="/z/d/html/4586.html" rel="external">"Liver transplantation in adults: Initial and maintenance immunosuppression"</a>.)</p><p class="headingAnchor" id="H3822522481"><span class="h3">Patients with RAI ≥5</span></p><p class="headingAnchor" id="H422846042"><span class="h4">Initial therapy</span><span class="headingEndMark"> — </span>For patients with biopsy-proven moderate to severe acute TCMR (ie, RAI ≥5), initial therapy consists of high-dose glucocorticoids (eg, <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>) followed by a glucocorticoid taper, in addition to optimizing the maintenance immunosuppression regimen (<a class="graphic graphic_algorithm graphicRef129097" href="/z/d/graphic/129097.html" rel="external">algorithm 1</a>) [<a href="#rid16">16,22,23</a>]. (See  <a class="medical medical_review" href="/z/d/html/4586.html" rel="external">"Liver transplantation in adults: Initial and maintenance immunosuppression"</a>.)</p><p><a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">Methylprednisolone</a> dosing varies among liver transplantation centers. We administer methylprednisolone in a daily bolus dose of 500 mg or 1000 mg intravenously for one to three days. A typical oral glucocorticoid taper would be to start <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 to 80 mg daily and to gradually reduce the dose over four weeks until a maintenance dose is reached (eg, prednisone 5 mg daily) or prednisone is discontinued. </p><p>For most patients with acute TCMR, biochemical response (ie, improvement of liver biochemical tests) to initial glucocorticoid therapy (in addition to optimizing the baseline immunosuppressive regimen) typically occurs within three to five days. For patients who do not have biochemical improvement within five days, biopsy of the liver allograft is repeated. If histology is consistent with acute TCMR, we typically give a second course of bolus <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>. For patients without a biochemical response within five days of a second course of bolus methylprednisolone, subsequent pharmacologic options include antithymocyte globulin (ATG). </p><p>For patients who do not respond to initial bolus glucocorticoid therapy and who have biopsy-confirmed acute TCMR, some liver transplantation centers do not give a second course of bolus <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> but proceed directly to subsequent therapy (eg, ATG). (See <a class="local">'Therapy for nonresponders'</a> below.)</p><p>While most patients respond to glucocorticoid therapy, few high-quality studies have compared the efficacy of various glucocorticoid regimens for the treatment of acute TCMR [<a href="#rid24">24</a>]. In a trial including 38 patients with acute TCMR of the liver allograft, <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (1 g bolus intravenously) followed by a six day glucocorticoid taper (ie, from 200 mg daily to 20 mg daily) resulted in higher rates of histologic resolution of acute rejection compared with methylprednisolone 1 g boluses given for three consecutive days (83 versus 50 percent) [<a href="#rid24">24</a>]. In addition, infection rates were lower in patients given a single methylprednisolone dose followed by <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> taper (55 versus 90 percent). </p><p class="headingAnchor" id="H635754998"><span class="h4">Managing glucocorticoid-related toxicity</span><span class="headingEndMark"> — </span>The major complication of glucocorticoids is increased susceptibility to infection, especially oral candidiasis, cytomegalovirus (CMV), <em>Aspergillus</em>, <em>Pneumocystis jirovecii</em> (previously referred to as <em>P. carinii</em>), and bacterial pathogens [<a href="#rid24">24</a>]. Other potential problems include hyperglycemia, hypertension, peptic ulcer disease, and psychiatric disturbances including euphoria and depression. </p><p>For patients with acute TCMR who are treated with high-dose glucocorticoids, our approach to managing treatment-related toxicity includes (see  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>During the glucocorticoid bolus therapy phase of treatment:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Blood glucose levels are monitored daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For ulcer prophylaxis, a proton pump inhibitor is given daily and is continued during the glucocorticoid taper. (See  <a class="medical medical_review" href="/z/d/html/25.html" rel="external">"Peptic ulcer disease: Treatment and secondary prevention", section on 'Maintenance antisecretory therapy'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For all patients treated with high-dose glucocorticoids, antimicrobial and antiviral prophylaxis includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CMV polymerase chain reaction (PCR) testing is performed monthly for three months, and for high-risk recipients (ie, donor CMV positive/recipient CMV negative), CMV prophylaxis is given for three months. The approach to CMV prophylaxis in the liver transplant recipient is discussed separately:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">"Infectious complications in liver transplantation", section on 'Cytomegalovirus'</a>.)</p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation", section on 'Cytomegalovirus'</a>.)</p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/z/d/html/8305.html" rel="external">"Approach to the diagnosis of cytomegalovirus infection"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For<em> P. jirovecii </em>prophylaxis, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> is given for three months. Prevention of <em>P. jirovecii </em>pneumonia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">"Infectious complications in liver transplantation", section on 'Antibacterial prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation", section on 'Pneumocystis pneumonia'</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Therapy for nonresponders</span><span class="headingEndMark"> — </span>While most patients with acute TCMR rejection respond to optimizing baseline immunosuppression and glucocorticoid therapy, some patients do not respond to initial antirejection treatment [<a href="#rid22">22,25</a>]. Therapeutic options such as ATG have been used to treat patients with glucocorticoid-refractory rejection.</p><p class="headingAnchor" id="H7"><span class="h3">Antithymocyte globulin</span><span class="headingEndMark"> — </span>ATG is an option for patients with glucocorticoid-refractory acute TCMR that has been confirmed with biopsy of the liver allograft. ATG is a polyclonal <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> that induces T lymphocyte depletion in the peripheral blood primarily by complement-dependent cell lysis [<a href="#rid26">26</a>]. ATG also contains some B cell-specific antibodies that inhibit B cell proliferation and induce B cell apoptosis. </p><p>Prior to initiating ATG, we obtain quantitative PCR testing for CMV and Epstein-Barr virus (EBV). The risk of and monitoring for viral infections in transplant recipients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">"Infectious complications in liver transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient", section on 'CMV and EBV'</a> and  <a class="medical medical_review" href="/z/d/html/8291.html" rel="external">"Overview of diagnostic tests for cytomegalovirus infection"</a>.)</p><p>The optimal ATG dosing for treating glucocorticoid-refractory TCMR has not been well defined. We typically administer ATG 1.5 mg/kg daily, intravenously, for five to seven days. The ATG dose is titrated to achieve an absolute lymphocyte count ≤200 cells/microL. Prior to the first two doses of ATG, patients receive preinfusion therapy with a glucocorticoid (<a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> or <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>), <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>, and <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> to minimize infusion reactions. In addition, some patients receive preinfusion therapy prior to the subsequent doses of ATG.  </p><p>During ATG therapy, we may lower the <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> dose or discontinue it, and we may also lower the <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> dose. </p><p>Liver biochemical tests are obtained daily to assess response to therapy. White blood cell, absolute lymphocyte, and platelet counts are obtained daily to monitor for adverse effects. </p><p>We obtain a liver biopsy on day 7 of ATG therapy in patients without improvement in liver biochemistries to assess for histologic response. </p><p>Patients with glucocorticoid-refractory acute TCMR continue antimicrobial and antiviral prophylaxis that was initiated during glucocorticoid bolus therapy. (See <a class="local">'Initial therapy'</a> above.)</p><p>Limited data have suggested that ATG therapy was associated with histologic improvement in patients with glucocorticoid-refractory acute rejection of the liver allograft [<a href="#rid22">22,27,28</a>]. In a case series of 20 patients who had 21 episodes of acute TCMR, ATG therapy was associated with histologic improvement or resolution by day seven for 18 patients (90 percent) [<a href="#rid22">22</a>]. Three-year graft and patient survival rates were 60 and 65 percent, respectively.</p><p class="headingAnchor" id="H8"><span class="h3">Other pharmacologic options</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">Basiliximab</a> is a monoclonal antibody that binds to the interleukin-2 (IL-2) receptor on T cells, and it has been used as induction immunosuppressive therapy after liver transplantation [<a href="#rid29">29</a>]. Basiliximab blocks IL-2-mediated T cell proliferation, and thus inhibits the T-cell response to alloantigens that produces allograft damage in patients with acute TCMR. (See  <a class="medical medical_review" href="/z/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy", section on 'Basiliximab'</a>.)</p><p>Limited data have suggested that IL-2 antibody therapy was associated with resolution of acute TCMR in some patients who did not respond to glucocorticoid therapy [<a href="#rid30">30-32</a>]. In a study including 16 patients with glucocorticoid-resistant acute TCMR, IL-2 receptor antibody therapy (ie, <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a> or daclizumab [no longer available]) was associated with resolution of glucocorticoid-refractory rejection in 12 patients (75 percent) [<a href="#rid31">31</a>]. Of the remaining four patients, two developed chronic rejection, one required repeat liver transplantation, and one died with graft failure. </p><p>In a case report, <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a> was used for treating a liver transplant recipient with recurrent, late onset TCMR characterized by de novo donor specific antibodies [<a href="#rid33">33</a>]. Belatacept is a fusion protein that binds CD80/86 on antigen-presenting cells (APC) and blocks costimulation of T cells by APC ligands by preventing binding of CD80/86 to CD28 on T cells [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H3064362424"><span class="h2">Repeat liver transplantation</span><span class="headingEndMark"> — </span>Approximately five percent of liver transplantation recipients who develop acute TCMR progress to chronic rejection despite antirejection therapy [<a href="#rid22">22</a>] (see <a class="local">'Outcomes'</a> below). Some patients with chronic rejection may require retransplantation, and management of such patients requires a multidisciplinary approach (transplant hepatology, transplant surgery, pharmacology). Adjusting immunosuppression for patients with chronic rejection during the perioperative period is individualized, and the goal is to reduce the risk of infectious complications. (See  <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">"Infectious complications in liver transplantation"</a>.)</p><p class="headingAnchor" id="H2302422535"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Data have suggested that up to 4 percent of liver transplantation recipients develop chronic rejection [<a href="#rid35">35,36</a>]. The risk of chronic rejection appears to be increased in patients who have had repeated episodes of acute TCMR [<a href="#rid37">37</a>].</p><p>Studies of the long-term impact of acute TCMR have used different post-transplant time points to define early and late rejection and have yielded mixed results [<a href="#rid38">38-42</a>]. Older studies suggested that early acute rejection (ie, within three months of liver transplantation) did not adversely affect graft or patient outcomes [<a href="#rid38">38-40</a>]. In contrast, data from two large cohorts of liver transplant recipients (Adult to Adult Living Donor Liver Transplantation [A2ALL] and Scientific Registry of Transplant Recipients [SRTR] cohorts) found that acute rejection within six months post-transplant was associated with higher risk of graft failure (hazard ratio [HR] 1.91, 95% CI 1.21-3.01; and HR 1.77, 95% CI 1.63-1.92, respectively) and death (HR 1.86, 95% CI 1-3.47; and HR 1.66, 95% CI 1.52-1.83, respectively) [<a href="#rid41">41</a>]. In a subsequent study of 787 transplant recipients who underwent protocol liver biopsies, late TCMR (ie, &gt;6 weeks after transplant) was associated with increased risk of graft loss or mortality, whereas early, mild TCMR (ie, within six weeks of transplant) was not associated with adverse outcomes [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/4587.html" rel="external">"Liver transplantation in adults: Clinical manifestations and diagnosis of acute T-cell mediated (cellular) rejection of the liver allograft", section on 'Epidemiology'</a>.)</p><p>The impact of successfully treating acute TCMR on graft outcomes has not been well studied. Greater histologic severity of acute TCMR, later onset of rejection, and lack of response to antirejection therapy have been associated with worse graft outcomes (eg, progression to chronic rejection, graft loss) [<a href="#rid41">41-44</a>]. </p><p class="headingAnchor" id="H1745228427"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H1284850473"><span class="h2">Patients with subclinical rejection</span><span class="headingEndMark"> — </span>Subclinical acute TCMR rejection of the liver allograft is detected in patients with histologic evidence of acute rejection on biopsy without elevated liver biochemical tests (eg, aspartate aminotransferase [AST], alanine aminotransferase [ALT]). However, subclinical acute rejection is rarely recognized because protocol biopsies in the absence of abnormal liver biochemical tests are not routinely performed at most transplantation centers. The use of protocol biopsies is generally restricted to patients undergoing investigational immunosuppressive treatments, and whether antirejection therapy improves outcomes for patients with subclinical rejection is uncertain. Older data have suggested that patients with subclinical rejection may experience histologic improvement without modifying immunosuppression and that such subclinical immune activation might be beneficial for inducing a degree of tolerance [<a href="#rid5">5,44</a>].</p><p class="headingAnchor" id="H3719145180"><span class="h2">Patients with hepatitis C virus infection</span><span class="headingEndMark"> — </span>Management of acute TCMR in patients with hepatitis C virus (HCV) infection has required special attention because some histologic features, such as bile duct injury and portal lymphocytic inflammation, are found in both acute TCMR and recurrent HCV infection (see  <a class="medical medical_review" href="/z/d/html/4583.html" rel="external">"Hepatitis C virus infection in liver transplant candidates and recipients", section on 'Evaluation of HCV infection post-transplant'</a>). Thus, differentiating acute rejection in the setting of HCV infection from HCV infection alone can be difficult on histologic grounds. (See  <a class="medical medical_review" href="/z/d/html/4587.html" rel="external">"Liver transplantation in adults: Clinical manifestations and diagnosis of acute T-cell mediated (cellular) rejection of the liver allograft", section on 'Establishing the diagnosis'</a>.)</p><p>During the era of peginterferon therapy for HCV infection, glucocorticoid or T-cell depletion therapies were associated with more severe histologic HCV recurrence, accelerated progression to fibrosis, and increased mortality [<a href="#rid45">45-49</a>]. However, the availability of safe and effective HCV therapy with direct-acting antivirals has revolutionized the approach to HCV management in liver transplant candidates and recipients [<a href="#rid50">50,51</a>]. Thus, the need to differentiate HCV recurrence from acute TCMR is uncommon because many patients are successfully treated for HCV infection before liver transplantation, and those who are not treated pretransplantation often receive antiviral therapy early post-transplantation. </p><p class="headingAnchor" id="H3917258825"><span class="h2">Patients with autoimmune liver disease</span><span class="headingEndMark"> — </span>Autoimmune liver disease has been associated with an increased risk of glucocorticoid-refractory acute rejection. In a study of 413 living donor liver transplant recipients, autoimmune liver disease was associated with higher rates of glucocorticoid-refractory acute TCMR compared with recipients with other causes of liver disease (53 versus 40 percent) [<a href="#rid4">4</a>]. In addition, autoimmune liver disease was associated with increased risk of acute TCMR (odds ratio [OR] 2.61; 95% CI 1.48-4.60). (See  <a class="medical medical_review" href="/z/d/html/3659.html" rel="external">"Management of autoimmune hepatitis", section on 'Disease course'</a>.)</p><p class="headingAnchor" id="H1295718118"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113977.html" rel="external">"Society guideline links: Liver transplantation"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background </strong>– The use of potent immunosuppressive agents for induction and maintenance therapy following liver transplantation has reduced the incidence of acute T cell-mediated (cellular) rejection (TCMR), which is defined as liver allograft dysfunction associated with specific histologic changes in the graft. With use of immunosuppression protocols, acute TCMR occurs in approximately 10 to 30 percent of liver transplantation recipients. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy </strong>– For patients with acute TCMR, the goals of treatment are (see <a class="local">'Goals of therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improving liver biochemical tests and liver histology</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preventing chronic rejection</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoiding adverse impact on long-term graft and patient survival</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures </strong>– For all patients with histologic evidence of acute TCMR of the liver allograft, the baseline immunosuppressive regimen is optimized, while the specific approach depends on the patient's existing regimen and baseline kidney function. For example, higher levels of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> may be targeted or an antimetabolite (<a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>) may be added to the baseline drug regimen. (See <a class="local">'Optimizing baseline immunosuppression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defining severity of rejection</strong> – The management of patients with histologic evidence of acute TCMR is guided by histopathologic severity of rejection and the rejection activity index (RAI) (<a class="graphic graphic_table graphicRef74243" href="/z/d/graphic/74243.html" rel="external">table 1</a>). Mild rejection has been regarded as RAI ≤4, while classification of RAI values has varied among studies. (See <a class="local">'Defining severity of rejection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with moderate to severe TCMR</strong> – For patients with biopsy-proven moderate to severe acute TCMR (ie, RAI ≥5), we suggest glucocorticoid therapy in addition to optimizing baseline immunosuppression (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically administer <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> in a daily bolus dose of 500 mg or 1000 mg intravenously for one to three days, followed by a gradual <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> taper (<a class="graphic graphic_algorithm graphicRef129097" href="/z/d/graphic/129097.html" rel="external">algorithm 1</a>). (See <a class="local">'Patients with RAI ≥5'</a> above.)</p><p></p><p class="bulletIndent1">For all patients treated with high-dose glucocorticoids, antimicrobial and antiviral prophylaxis includes (see <a class="local">'Managing glucocorticoid-related toxicity'</a> above and  <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/4586.html" rel="external">"Liver transplantation in adults: Initial and maintenance immunosuppression", section on 'Managing glucocorticoid-related toxicity'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cytomegalovirus (CMV) polymerase chain reaction (PCR) testing is performed monthly for three months, and for high-risk recipients (ie, donor CMV positive/recipient CMV negative) CMV prophylaxis is given for three months. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For<em> P. jirovecii </em>prophylaxis, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> is given for three months. </p><p></p><p class="bulletIndent1">The indications for and duration of antimicrobial and antiviral prophylaxis for liver transplant recipients are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4588.html" rel="external">"Infectious complications in liver transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – The impact of successfully treating acute TCMR on graft outcomes has not been well studied. Greater histologic severity of acute TCMR, later onset of rejection (&gt;3 months post-transplant), and lack of response to antirejection therapy have been associated with worse graft outcomes (eg, progression to chronic rejection, graft loss). (See <a class="local">'Outcomes'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Maluf DG, Stravitz RT, Cotterell AH, et al. Adult living donor versus deceased donor liver transplantation: a 6-year single center experience. Am J Transplant 2005; 5:149.</a></li><li><a class="nounderline abstract_t">Gruttadauria S, Vasta F, Mandalà L, et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. Transplant Proc 2005; 37:2611.</a></li><li><a class="nounderline abstract_t">Rodríguez-Perálvarez M, Rico-Juri JM, Tsochatzis E, et al. Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. Transpl Int 2016; 29:961.</a></li><li><a class="nounderline abstract_t">Shindoh J, Akamatsu N, Tanaka T, et al. Risk factors for acute liver allograft rejection and their influences on treatment outcomes of rescue therapy in living donor liver transplantation. Clin Transplant 2016; 30:880.</a></li><li><a class="nounderline abstract_t">Goddard S, Adams DH. Methylprednisolone therapy for acute rejection: too much of a good thing? Liver Transpl 2002; 8:535.</a></li><li><a class="nounderline abstract_t">De Martin E, Londoño MC, Emamaullee J, et al. The optimal immunosuppression management to prevent early rejection after liver transplantation: A systematic review of the literature and expert panel recommendations. Clin Transplant 2022; 36:e14614.</a></li><li><a class="nounderline abstract_t">Terrault NA, Francoz C, Berenguer M, et al. Liver Transplantation 2023: Status Report, Current and Future Challenges. Clin Gastroenterol Hepatol 2023; 21:2150.</a></li><li><a class="nounderline abstract_t">Gibbs JF, Husberg BS, Klintmalm GB, et al. Outcome analysis of FK 506 therapy for acute and chronic rejection. Transplant Proc 1993; 25:622.</a></li><li><a class="nounderline abstract_t">Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation 1992; 53:1056.</a></li><li><a class="nounderline abstract_t">Klupp J, Bechstein WO, Platz KP, et al. Mycophenolate mofetil added to immunosuppression after liver transplantation--first results. Transpl Int 1997; 10:223.</a></li><li><a class="nounderline abstract_t">Hebert MF, Ascher NL, Lake JR, et al. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999; 67:707.</a></li><li><a class="nounderline abstract_t">Pfitzmann R, Klupp J, Langrehr JM, et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation 2003; 76:130.</a></li><li><a class="nounderline abstract_t">Akamatsu N, Sugawara Y, Tamura S, et al. Efficacy of mycofenolate mofetil for steroid-resistant acute rejection after living donor liver transplantation. World J Gastroenterol 2006; 12:4870.</a></li><li><a class="nounderline abstract_t">Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25:658.</a></li><li><a class="nounderline abstract_t">Demetris AJ, Bellamy C, Hübscher SG, et al. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant 2016; 16:2816.</a></li><li><a class="nounderline abstract_t">Charlton M, Levitsky J, Aqel B, et al. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation 2018; 102:727.</a></li><li><a class="nounderline abstract_t">Höroldt BS, Burattin M, Gunson BK, et al. Does the Banff rejection activity index predict outcome in patients with early acute cellular rejection following liver transplantation? Liver Transpl 2006; 12:1144.</a></li><li><a class="nounderline abstract_t">Bolognesi M, Sacerdoti D, Mescoli C, et al. Acute liver rejection: accuracy and predictive values of doppler US measurements--initial experience. Radiology 2005; 235:651.</a></li><li><a class="nounderline abstract_t">Demetris AJ, Ruppert K, Dvorchik I, et al. Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation 2002; 74:1290.</a></li><li><a class="nounderline abstract_t">Netto GJ, Watkins DL, Williams JW, et al. Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: the "hepatitis C 3" multi-institutional trial experience. Arch Pathol Lab Med 2006; 130:1157.</a></li><li><a class="nounderline abstract_t">Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000; 31:792.</a></li><li><a class="nounderline abstract_t">Palmer WC, Taner CB, Keaveny AP, et al. Antithymocyte Globulin Use for Corticosteroid Nonresponsive Rejection After Liver Transplantation. Transplant Proc 2018; 50:3606.</a></li><li><a class="nounderline abstract_t">Cattral MS, Lilly LB, Levy GA. Immunosuppression in liver transplantation. Semin Liver Dis 2000; 20:523.</a></li><li><a class="nounderline abstract_t">Volpin R, Angeli P, Galioto A, et al. Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial. Liver Transpl 2002; 8:527.</a></li><li><a class="nounderline abstract_t">Andreu H, Rimola A, Bruguera M, et al. Acute cellular rejection in liver transplant recipients under cyclosporine immunosuppression: predictive factors of response to antirejection therapy. Transplantation 2002; 73:1936.</a></li><li><a class="nounderline abstract_t">Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79:1507.</a></li><li><a class="nounderline abstract_t">Benjamin MM, Dasher KJ, Trotter JF. A comparison of outcomes between OKT3 and antithymocyte globulin for treatment of steroid-resistant rejection in hepatitis C liver transplant recipients. Transplantation 2014; 97:470.</a></li><li><a class="nounderline abstract_t">Schmitt TM, Phillips M, Sawyer RG, et al. Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation. Dig Dis Sci 2010; 55:3224.</a></li><li><a class="nounderline abstract_t">Ramirez CB, Doria C, di Francesco F, et al. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months. J Surg Res 2007; 138:198.</a></li><li><a class="nounderline abstract_t">Fernandes ML, Lee YM, Sutedja D, et al. Treatment of steroid-resistant acute liver transplant rejection with basiliximab. Transplant Proc 2005; 37:2179.</a></li><li><a class="nounderline abstract_t">Orr DW, Portmann BC, Knisely AS, et al. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation. Transplant Proc 2005; 37:4373.</a></li><li><a class="nounderline abstract_t">Togashi J, Sugawara Y, Tamura S, et al. Basiliximab as therapy for acute rejection after liver transplantation for hepatitis C virus cirrhosis. Biosci Trends 2011; 5:57.</a></li><li><a class="nounderline abstract_t">Klintmalm GB, Trotter JF, Demetris A. Belatacept Treatment of Recurrent Late-onset T Cell-mediated Rejection/Antibody-mediated Rejection With De Novo Donor-specific Antibodies in a Liver Transplant Patient. Transplant Direct 2022; 8:e1076.</a></li><li><a class="nounderline abstract_t">Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med 2016; 374:333.</a></li><li><a class="nounderline abstract_t">Wiesner RH, Menon KV. Late hepatic allograft dysfunction. Liver Transpl 2001; 7:S60.</a></li><li><a class="nounderline abstract_t">Jain A, Demetris AJ, Kashyap R, et al. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl 2001; 7:623.</a></li><li><a class="nounderline abstract_t">Soin AS, Rasmussen A, Jamieson NV, et al. CsA levels in the early posttransplant period--predictive of chronic rejection in liver transplantation? Transplantation 1995; 59:1119.</a></li><li><a class="nounderline abstract_t">Neuberger J, Adams DH. What is the significance of acute liver allograft rejection? J Hepatol 1998; 29:143.</a></li><li><a class="nounderline abstract_t">Dousset B, Conti F, Cherruau B, et al. Is acute rejection deleterious to long-term liver allograft function? J Hepatol 1998; 29:660.</a></li><li><a class="nounderline abstract_t">Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28:638.</a></li><li><a class="nounderline abstract_t">Levitsky J, Goldberg D, Smith AR, et al. Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients. Clin Gastroenterol Hepatol 2017; 15:584.</a></li><li><a class="nounderline abstract_t">Jadlowiec CC, Morgan PE, Nehra AK, et al. Not All Cellular Rejections Are the Same: Differences in Early and Late Hepatic Allograft Rejection. Liver Transpl 2019; 25:425.</a></li><li><a class="nounderline abstract_t">Thurairajah PH, Carbone M, Bridgestock H, et al. Late acute liver allograft rejection; a study of its natural history and graft survival in the current era. Transplantation 2013; 95:955.</a></li><li><a class="nounderline abstract_t">Bartlett AS, Ramadas R, Furness S, et al. The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic liver transplantation: a systematic review. Liver Transpl 2002; 8:1147.</a></li><li><a class="nounderline abstract_t">Schluger LK, Sheiner PA, Thung SN, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23:971.</a></li><li><a class="nounderline abstract_t">Rosen HR, Shackleton CR, Higa L, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92:1453.</a></li><li><a class="nounderline abstract_t">Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5:S107.</a></li><li><a class="nounderline abstract_t">Berenguer M, Prieto M, Córdoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28:756.</a></li><li><a class="nounderline abstract_t">Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol 2012; 56:973.</a></li><li><a class="nounderline abstract_t">Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 2015; 149:649.</a></li><li><a class="nounderline abstract_t">Saxena V, Khungar V, Verna EC, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. Hepatology 2017; 66:1090.</a></li></ol></div><div id="topicVersionRevision">Topic 4598 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15636624" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Adult living donor versus deceased donor liver transplantation: a 6-year single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16182762" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26714264" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27146588" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Risk factors for acute liver allograft rejection and their influences on treatment outcomes of rescue therapy in living donor liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12037784" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Methylprednisolone therapy for acute rejection: too much of a good thing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35143096" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The optimal immunosuppression management to prevent early rejection after liver transplantation: A systematic review of the literature and expert panel recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37084928" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Liver Transplantation 2023: Status Report, Current and Future Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7679823" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Outcome analysis of FK 506 therapy for acute and chronic rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1374944" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9163864" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mycophenolate mofetil added to immunosuppression after liver transplantation--first results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10096526" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12865798" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16937470" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of mycofenolate mofetil for steroid-resistant acute rejection after living donor liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9049215" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Banff schema for grading liver allograft rejection: an international consensus document.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27273869" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29485508" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16799959" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Does the Banff rejection activity index predict outcome in patients with early acute cellular rejection following liver transplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15770040" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acute liver rejection: accuracy and predictive values of doppler US measurements--initial experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451268" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Real-time monitoring of acute liver-allograft rejection using the Banff schema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16886238" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: the "hepatitis C 3" multi-institutional trial experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706577" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30577245" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Antithymocyte Globulin Use for Corticosteroid Nonresponsive Rejection After Liver Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11200420" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Immunosuppression in liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12037783" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12131692" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Acute cellular rejection in liver transplant recipients under cyclosporine immunosuppression: predictive factors of response to antirejection therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15940039" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24142032" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A comparison of outcomes between OKT3 and antithymocyte globulin for treatment of steroid-resistant rejection in hepatitis C liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20238251" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17292404" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15964372" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment of steroid-resistant acute liver transplant rejection with basiliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16387124" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21572248" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Basiliximab as therapy for acute rejection after liver transplantation for hepatitis C virus cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35774420" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Belatacept Treatment of Recurrent Late-onset T Cell-mediated Rejection/Antibody-mediated Rejection With De Novo Donor-specific Antibodies in a Liver Transplant Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26816011" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Belatacept and Long-Term Outcomes in Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11689778" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Late hepatic allograft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11460230" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7732557" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : CsA levels in the early posttransplant period--predictive of chronic rejection in liver transplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9696504" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : What is the significance of acute liver allograft rejection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9824277" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Is acute rejection deleterious to long-term liver allograft function?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731552" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27567694" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30615251" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Not All Cellular Rejections Are the Same: Differences in Early and Late Hepatic Allograft Rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23442806" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Late acute liver allograft rejection; a study of its natural history and graft survival in the current era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12474154" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic liver transplantation: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8621177" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9317061" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10431024" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9625309" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21963518" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Immunosuppression and HCV recurrence after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25985734" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28504842" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
